The β-arrestin1/endothelin axis bolsters ovarian fibroblast-dependent invadosome activity and cancer cell metastatic potential

Danila Del Rio,Ilenia Masi,Valentina Caprara,Flavia Ottavi,Gabriele Albertini Petroni,Erica Salvati,Daniela Trisciuoglio,Sara Maria Giannitelli,Anna Bagnato,Emanuele Mauri,Francesca Spadaro,Laura Rosanò

DOI: https://doi.org/10.1038/s41419-024-06730-6

2024-05-23

Cell Death and Disease

Abstract:Recruitment of fibroblasts to tumors and their activation into cancer-associated fibroblasts (CAFs) is a strategy used by tumor cells to direct extracellular matrix (ECM) remodeling, invasion, and metastasis, highlighting the need to investigate the molecular mechanisms driving CAF function. Endothelin-1 (ET-1) regulates the communication between cancer and stroma and facilitates the progression of serous ovarian cancer (SOC). By binding to Endothelin A (ET A ) and B (ET B ) receptors, ET-1 enables the recruitment of β-arrestin1 (β-arr1) and the formation of signaling complexes that coordinate tumor progression. However, how ET-1 receptors might "educate" human ovarian fibroblasts (HOFs) to produce altered ECM and promote metastasis remains to be elucidated. This study identifies ET-1 as a pivotal factor in the activation of CAFs capable of proteolytic ECM remodeling and the generation of heterotypic spheroids containing cancer cells with a propensity to metastasize. An autocrine/paracrine ET-1/ET A/B R/β-arr1 loop enhances HOF proliferation, upregulates CAF marker expression, secretes pro-inflammatory cytokines, and increases collagen contractility, and cell motility. Furthermore, ET-1 facilitates ECM remodeling by promoting the lytic activity of invadosome and activation of integrin β1. In addition, ET-1 signaling supports the formation of heterotypic HOF/SOC spheroids with enhanced ability to migrate through the mesothelial monolayer, and invade, representing metastatic units. The blockade of ET A/B R or β-arr1 silencing prevents CAF activation, invadosome function, mesothelial clearance, and the invasive ability of heterotypic spheroids. In vivo, therapeutic inhibition of ET A/B R using bosentan (BOS) significantly reduces the metastatic potential of combined HOFs/SOC cells, associated with enhanced apoptotic effects on tumor cells and stromal components. These findings support a model in which ET-1/β-arr1 reinforces tumor/stroma interaction through CAF activation and fosters the survival and metastatic properties of SOC cells, which could be counteracted by ET A/B R antagonists.

cell biology

What problem does this paper attempt to address?

The paper primarily explores the mechanisms of β-arrestin1 (β-arr1) and the endothelin axis in human ovarian fibroblasts (HOFs) and their impact on the metastatic potential of cancer cells.

Specifically, the study addresses the following key issues:

1. **Mechanism of Endothelin-1 (ET-1)**: The paper reveals how ET-1 activates β-arr1 by binding to endothelin A (ET_A) and endothelin B (ET_B) receptors, further promoting the transformation of fibroblasts into cancer-associated fibroblasts (CAFs). This process enhances fibroblast proliferation, secretion of pro-inflammatory cytokines, collagen contraction ability, and cell migration capacity.

2. **ECM Remodeling and Formation of Invasive Structures**: The paper points out that ET-1 supports ECM (extracellular matrix) remodeling by promoting the activity of invasive structures (invadosomes) and the activation of integrin β1. These invasive structures can locally degrade the ECM, thereby facilitating cancer cell invasion and metastasis.

3. **Formation of Heterotypic Spheroids and Metastatic Potential**: The study finds that ET-1 promotes the formation of heterotypic spheroids between HOFs and ovarian cancer cells. These spheroids have a stronger ability to traverse the mesothelial monolayer and are more invasive, representing metastatic units.

4. **Therapeutic Interventions**: By inhibiting ET_A/ET_B receptors or silencing β-arr1, the activation of CAFs, the function of invasive structures, and the invasiveness of heterotypic spheroids can be prevented. Additionally, in vivo experiments show that using the ET_A/ET_B receptor antagonist bosentan significantly reduces the co-metastatic potential of HOFs and ovarian cancer cells and enhances the apoptotic effects on tumor cells and stromal components.

In summary, this paper, through detailed experimental data and analysis, reveals the crucial role of the ET-1/β-arr1 axis in promoting ovarian fibroblast activation and ECM remodeling, and proposes a new strategy to inhibit ovarian cancer metastasis by targeting this axis.